IO Biotech to explore strategic alternatives including merger, sale, or liquidation

IO Biotech, Inc.

Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.
Further reduction-in-force and cost-cutting measures are also under consideration.
No timetable for the process; no assurance any transaction will occur.
IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-017164
form_type: 8-K
ticker: IOBTQ
cik: 0001865494
company_name: IO Biotech, Inc.
filed_at: 2026-01-21T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.604322+00:00
generated_at: 2026-05-16T09:21:14.598561+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-017164
json_url: https://secwatch.observer/filing/0001193125-26-017164.json
markdown_url: https://secwatch.observer/filing/0001193125-26-017164.md
text_url: https://secwatch.observer/filing/0001193125-26-017164.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/0001193125-26-017164-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/d26457d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-017164

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.